2023
DOI: 10.1016/j.cell.2023.02.039
|View full text |Cite
|
Sign up to set email alerts
|

Advances in cancer immunotherapies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
24
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 82 publications
(24 citation statements)
references
References 0 publications
0
24
0
Order By: Relevance
“…Each type of immunotherapy is specifically tailored to different types of cancer. Gliomas, for example, can be treated with four main types of immunotherapies: ICBs, OVs, vaccines, and CAR‐T cell therapies 95–98 . ICB therapy has proven effective in blocking immune checkpoints such as PD‐1/PD‐L1, thereby preventing the immunosuppressive effect.…”
Section: Glioma Immunotherapiesmentioning
confidence: 99%
“…Each type of immunotherapy is specifically tailored to different types of cancer. Gliomas, for example, can be treated with four main types of immunotherapies: ICBs, OVs, vaccines, and CAR‐T cell therapies 95–98 . ICB therapy has proven effective in blocking immune checkpoints such as PD‐1/PD‐L1, thereby preventing the immunosuppressive effect.…”
Section: Glioma Immunotherapiesmentioning
confidence: 99%
“…Cancer immunotherapy has made breakthroughs in the treatment of a wide range of cancers. 1 Among the various tumor immunotherapies, therapeutic tumor vaccines have been studied for several decades and have shown signs of efficacy to help patients resistant to other immunotherapies, despite the limited clinical progress. 2,3 It was proposed that cancer vaccines have the potential to become standard anticancer therapies in the near future.…”
Section: Introductionmentioning
confidence: 99%
“…Cancer immunotherapy has made breakthroughs in the treatment of a wide range of cancers . Among the various tumor immunotherapies, therapeutic tumor vaccines have been studied for several decades and have shown signs of efficacy to help patients resistant to other immunotherapies, despite the limited clinical progress. , It was proposed that cancer vaccines have the potential to become standard anticancer therapies in the near future. With the rapid development of nanotechnology, multifunctional nanovaccines have attracted great attention owing to the potential to elicit a strong tumor-specific immune response and establish long-term immunogenic memory. , Relative to traditional vaccines, nanovaccines have exhibited unique advantages, such as high antigen/adjuvant loading, efficient targeting of lymph node and antigen presentation cells, tunable antigen cross-presentation to T cells, and decreased off-target side effects. In the past decades, various types of nanocarriers including exosomes, cell membrane or protein-based NPs, polymers and lipsomes, and inorganic and self-adjuvanted NPs have been developed to create cancer nanovaccines, paving the way for the rational design and preparation of efficient nanovaccines for immunotherapy. To elicit a robust and persistent immune response against tumors, vaccines need to trigger both innate and adaptive immune response.…”
Section: Introductionmentioning
confidence: 99%
“…In the past decade, immunotherapy has been explored as a potential therapeutic approach to combat against cancer. Among various types of immune-based therapies, cancer vaccines are considered to be a compelling strategy to eradicate cancer. It is essential to deliver appropriate tumor antigens or immunostimulatory adjuvants into antigen presenting cells (APCs) for inducing strong tumor-specific immunity. , Significantly, it is a fundamental challenge for cancer vaccines to adequately induce dendritic cell (DCs) maturation adequately. Moreover, the development of cancer vaccines has also been stalled by the lack of universal tumor-associated antigens (TAAs) and the difficulty of preparing and producing personalized vaccines in vitro .…”
Section: Introductionmentioning
confidence: 99%